Posted by Michael Wonder on 06 Aug 2024
Attralus receives breakthrough therapy designation for its pan-amyloid diagnostic PET imaging candidate 124I-evuzamitide (AT-01) for cardiac amyloidosis
5 August 2024 - A Phase 3 study for 124I-evuzamitide in patients with suspected cardiac amyloidosis is anticipated to begin in the first half of 2025.
Attralus today announced that its investigational diagnostic imaging agent drug, 124I-evuzamitide (AT-01), has been granted breakthrough therapy designation by the US FDA for positron emission tomography imaging in patients with suspected or known cardiac amyloidosis.
